FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the financial year ended May 31, 2004

Lorus Therapeutics Inc.
(Translation of registrant's name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7
(Address of principal executive offices)

[Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F.]

Form 20-F ___X___ Form 40-F __X__

[Indicate by check mark whether the registrant by
furnishing the information contained in this Form is also
thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes _____ No ____X___

[If "Yes" is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: October 14, 2004

By: "Shane Ellis"
Shane Ellis
Vice President, Legal Affairs
Corporate Secretary

Index for the 6-K filing

99.07 Press release: Lorus Therapeutics allowed European patent to protect unique tumor suppressor

99.08 Press release: Lorus Therapeutics participates at the 2004 annual meeting of the American Society of Clinical Oncology

99.09 Press release: Lorus Therapeutics Inc. presents progress in its product development programs at BIO 2004

99.10 Press release: Lorus Therapeutics achieves full patient enrollment in Virulizin(R) Phase III registration clinical trial

99.11 Press release: Lorus CEO Dr. Jim Wright to ring opening bell on the American Stock Exchange on Friday June 18, 2004

99.12 Press release: Webcast Alert: Lorus Therapeutics (Amex:LRP) Presentation at American Stock Exchange Annual Online Healthcare & Biotech Investor Conference

99.13 Press release: Lorus Therapeutics to be a sponsor of the 6th Annual Lustgarten Foundation Scientific Conference

99.14 Press release: Lorus expands prostate cancer trial of GTI-2501 with docetaxel to two additional sites in Canada

99.15 Press release: Lorus Therapeutics reports year end results for fiscal year 2004

99.16 Press release: Lorus Therapeutics Inc. presents Virulizin(R) at International Immunology Conference

99.17 Press release: Lorus Therapeutics Inc. to present results of novel anticancer small molecule studies

99.18 Press release: Positive clinical results observed in Lorus Therapeutics' clinical trial of GTI-2040

99.19 Press release: Lorus announces appointment of chief financial officer

99.20 Press release: Lorus publishes results of studies examining the mechanism by which Virulizin(R) acts as an antitumor agent

99.21 Press release: Lorus Therapeutics presents at Asia's largest biotechnology conference

99.22 Press release: Lorus Therapeutics to present at the UBS Global Life Sciences Conference

99.23 Press release: Lorus encouraged by Phase II interim clinical data providing evidence of disease stabilizations, tumor reductions, and a favourable safety profile with GTI-2040 in combination therapy in advanced renal cell carcinoma

99.24 Press release: Lorus Therapeutics to present at leading biotechnology conferences in Canada and Europe

99.25 Press release: Lorus announces $15 million convertible debenture financing

99.26 Press release: Lorus Therapeutics reports first quarter results for fiscal year 2005

Contacts:
Lorus Therapeutics Inc.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com

Canadian Media Contact:
Eliza Walsh
Mansfield Communications
Tel: (416) 599-0024
Email: eliza@mcipr.com

US Media Contact
Amy Banek
Mansfield Communications
Tel: (212) 370-5045
Email: amy@mcipr.com

LORUS THERAPEUTICS PRESENTS SCIENTIFIC RESULTS FOR TWO ANTI-CANCER DRUGS

-Research presented to the American Association For Cancer Research (AACR) Annual Conference-

TSX: LOR
AMEX: LRP

TORONTO, CANADA, March 30th, 2004 – Lorus Therapeutics Inc. ("Lorus") announced that it is participating at the AACR Annual Conference in Orlando, Florida, which will be held from March 27-31, 2004. Two presentations were accepted and will be published in the meeting proceedings.

The first presentation, entitled *Virulizin(R) Increases Infiltration of NK Cells to Tumors Via Activation of Macrophages* , summarizes the latest studies on the mechanism by which Virulizin acts as an anti-tumor agent. The aim of the study was to determine whether a subset of immune effector cells known as NK cells contribute to the observed anti-tumor efficacy of Virulizin(R).

Analysis of tumor samples from Virulizin(R)-treated mice showed an increase in the presence of both macrophages and NK cells within the tumor tissue as compared to tumor tissue from saline-treated mice. This response appeared to occur early in the treatment cycle and correlated with increased markers for programmed cell death within the tumors. Removal of macrophages from mice resulted in decreased numbers of NK cells in tumor samples, indicating the crucial involvement of macrophages in NK cell infiltration into tumors. In addition, NK-deficient mice did not respond to Virulizin treatment showing that NK cells are also important for inhibition of tumor growth by Virulizin(R).

These results indicate that Virulizin(R) can mediate a sustained expansion and infiltration of NK cells and macrophages into tumors, and that the interaction between these immune effector cells contributes significantly to the anti-tumor mechanism of Virulizin(R).

(more)

Virulizin(R) has been awarded orphan drug status and fast-track status by the United States Food and Drug Administration in clinical studies for the treatment of pancreatic cancer. Virulizin(R) is currently in a Pivotal Phase III clinical trial in North America and Europe for the treatment of pancreatic cancer in combination with gemcitabine. Virulizin(R) is approved in Mexico for the treatment of melanoma and is commercially available in Mexico through Lorus' marketing partner, Mayne Pharma

The second presentation entitled *GTI-2040 Displays Cooperative Anti-tumor Activity when Combined with Standard Chemotherapeutic Drugs* summarizes preclinical studies aimed at assessing the potential therapeutic application of GTI-2040 in combination with chemotherapy for the treatment of a variety of cancers. Previous studies demonstrated that GTI-2040, as a single agent, has excellent anti-tumor properties against a broad range of human tumors implanted into mice. The current study examined the effects of combining GTI-2040 with standard chemotherapeutic compounds including dacarbazine (DTIC), CPT-11, doxorubicin, cisplatin and taxol.

The anti-tumor activity of all tested combinations exceeded treatment with the single agents. In addition, GTI-2040 treatment resulted in excellent anti-tumor activity against chemotherapy resistant human breast, ovarian, colon and pancreatic tumors implanted into mice. Furthermore, combinations with standard drugs to which the tumors were sensitive demonstrated cooperative anti-tumor activity with GTI-2040. Taken together, the results support the application of GTI-2040 to a number of currently available treatments with the potential to act when patients develop drug resistance, which is in large part responsible for chemotherapy treatment failure.

Lorus recently described an interim analysis of results obtained in a Phase II renal cell carcinoma clinical trial and indicated its intent to progress the drug into a registration Phase II/III clinical program. In addition, GTI 2040 is in a multiple Phase II clinical program sponsored by the US National Cancer Institute for the treatment of six different cancers, four of which have already been initiated.

"Presentations at international conferences, such as those supported by the AACR, provide an opportunity for Lorus' scientists and clinical staff to obtain expert feedback on the progress of Lorus' preclinical and clinical pipelines," said Dr Jim Wright CEO of Lorus. "From a business perspective, this information is very valuable when assessing drug development pathways for our products."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of six clinical trials in a phase II clinical trials program and one phase III registration clinical trial. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights,
commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Contacts:
Lorus Therapeutics Inc.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com

Canadian Media Contact:
Hugh Mansfield
Mansfield Communications
Tel: (416) 599-0024
Email: hugh@mcipr.com

US Media Contact
Amy Banek
Mansfield Communications
Tel: (212) 370-5045
Email: amy@mcipr.com

TSX: LOR
AMEX: LRP

LORUS THERAPEUTICS REPORTS THIRD QUARTER RESULTS FOR FISCAL YEAR 2004

TORONTO, CANADA – **April 23, 2004** – Lorus Therapeutics Inc. ("Lorus") today reported financial results for the quarter ended February 29, 2004. Unless specified otherwise, all amounts are in Canadian dollars.

QUARTERLY HIGHLIGHTS

- Continued to make significant progress in the pivotal phase III clinical trial of Virulizin (R) in advanced pancreatic cancer. This clinical trial continues to enroll patients in over 100 sites globally and is on track to attain full enrollment later this year.
- Analyzed interim data from the phase II clinical trial of GTI-2040 in combination with capecitabine for patients with advanced renal cell carcinoma. Unaudited data showed that more than half of the 21 evaluable patients in this study exhibited disease stabilization, ranging up to eight months. Tumor shrinkages of index tumors compared to baseline measurements were also observed in some patients. The Company looks to further the development of GTI-2040 into a definitive phase II/III registration trial in renal cell carcinoma but likely in combination with a first-line approved therapy versus first-line therapy alone, in newly diagnosed patients.
- Initiated a fourth trial with GTI-2040 in combination with gemcitabine for the treatment of a variety of solid tumors as part of a broader clinical development program sponsored and coordinated by the US National Cancer Institute (NCI).
- Initiated a phase II clinical trial in hormone refractory prostate cancer patients with GTI-2501, one of the Company's lead antisense drug candidates at the Sunnybrook Regional Cancer Centre in Toronto.
- Published papers by Lorus scientists in prominent scientific journals and made presentations at several international conferences and meetings in the cancer research field.
- Obtained approval to list on the American Stock Exchange and commenced trading on the exchange on February 23, 2004.

"Lorus is committed to the battle against cancer as we aggressively develop our pipeline and advance our clinical programs together with our partners such as the US NCI," said Dr. Jim Wright, chief executive officer of Lorus, "Our objective is to build shareholder value by contributing to the well-being of cancer patients through therapies that are safe and effective. During our third quarter, we made steady progress towards our goal."

Net loss for the third quarter this year totaled $8,159,000 ($0.05 per share) compared to a loss of $3,802,000 ($0.02 per share) for the same quarter last year. The increase in net loss for the current quarter relates primarily to the continuation of the expanded Virulizin(R) Phase III clinical trial. On a year-to-date basis, the loss was $22,328,000 compared to $11,847,000 for the comparable period last year. The expanded Virulizin(R) Phase III clinical trial program, the increased manufacturing and compliance activities and the procurement of drug supply for the U.S. NCI-sponsored Phase II clinical trial programs for GTI-2040 contributed to the increase in the nine-month period ended February 29, 2004. As the Virulizin phase III trial nears full enrollment, our research and development costs have increased to current levels. The company expects that Virulizin(R) trial costs will continue at its current level for the next quarter and believes that it will decrease in subsequent quarters.

Product, royalty and license revenue was $2,000 for the quarter and $606,000 for the nine months ended February 29, 2004 compared to $27,000 for the same periods last year. Included in the nine month revenue is an initial license fee of $546,000 received from Cyclacel Limited in connection with the out- licensing of the Lorus' small molecule program. The Company had no Virulizin(R) revenue for the current quarter as Lorus filed a change in formulation for Virulizin(R) with the Mexican regulatory authority. The company does not anticipate revenue in 2004 from any of its other anticancer drugs currently under development.

Research and development expenses for the third quarter of fiscal 2004 increased to $7,340,000 compared to $2,876,000 for the same quarter last year. For the nine months ended February 29, 2004, research and development expenses increased to $20,189,000 compared to $9,246,000 for the same period last year. The increase in expenditure on research and development activities relates primarily to higher clinical trial and regulatory expenditures for the continuation of the pivotal Phase III clinical trial of Virulizin(R) for the treatment of advanced pancreatic cancer at over 100 worldwide sites; increased manufacturing and compliance activities in developing commercial scale production processes for Virulizin(R); and the upfront procurement of GTI-2040 drug for the US NCI in relation to the NCI-sponsored Phase II clinical trial programs.

General and administrative expenses for the third quarter of fiscal 2004 increased to $1,010,000 compared to $960,000 for the same quarter last year. For the nine months ended February 29, 2004, general and administrative expenses increased modestly to $3,417,000 compared to $3,060,000.

Depreciation and amortization for the third quarter of fiscal 2004 decreased to $108,000 compared to $224,000 for the same quarter last year. For the nine months ended February 29, 2004, depreciation and amortization was $306,000 compared to $483,000 for the same period last year. These decreases were due mainly to lower deferred stock based compensation amortization in current year.

At February 29, 2004 Lorus had cash and cash equivalents and short-term investments totaling $36.3 million compared to $25.1 million at May 31, 2003. Working capital was $29.8 million at February 29, 2004 compared to $20.9 million at May 31, 2003.

(Amounts in 000's except for per common share data)	**Three months ended**	Three months ended	**Nine months ended**	Nine months ended
(Canadian Dollars)	**Feb. 29, 2004**	Feb. 28, 2003	**Feb. 29, 2004**	Feb. 28, 2003
Revenues (note 2)	**$ 2**	27	**606**	27
	2	27	**606**	27
EXPENSES				
Cost of Sales	**1**	27	**27**	27
Research and development	**7,340**	2,876	**20,189**	9,246
General and administrative	**1,010**	960	**3,417**	3,060
Depreciation and amortization	**108**	224	**306**	483
Operating Expenses	**8,459**	4,087	**23,939**	12,816
Interest and other income	**(298)**	(258)	**(1,005)**	(942)
Loss for the period	**8,159**	3,802	**22,328**	11,847
Deficit, beginning of period	**105,672**	82,914	**91,503**	74,869
Deficit, end of period	**$ 113,831**	$ 86,716	**$ 113,831**	$ 86,716
Basic and diluted loss per common share	**$ 0.05**	$ 0.02	**$ 0.13**	$ 0.08
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per share	**171,697**	144,433	**171,590**	144,424

Media, members of the financial community and shareholders are invited to listen to the Company's quarterly earnings presentation through an audio webcast on the company's website at www.lorusthera.com on Tuesday April 27, 2004.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical developments and marketing may be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

For further information:

Lorus Therapeutics Inc.
Corporate Communications
Grace Tse
Tel: (416) 798-1200 ext. 380
Email: ir@lorusthera.com

Mansfield Communications
Canadian Media Contact
Eliza Walsh
Tel: (416) 599-0024
Email: eliza@mcipr.com

Mansfield Communications
US Media Contact
Amy Banek
Tel: (212) 370-5045
E-mail: amy@mcipr.com

LORUS THERAPEUTICS PRESENTS ITS ANTISENSE ANTICANCER DRUGS PORTFOLIO AT TIDES 2004 INTERNATIONAL CONFERENCE

TSX: LOR
AMEX: LRP

TORONTO, CANADA, April 29, 2004 – Lorus Therapeutics Inc. ("Lorus") announced that it is presenting at the TIDES Conference being held in Las Vegas, NV, from April 25-29, 2004. An invited oral presentation entitled " *Lorus Therapeutics Antisense Drug Development: Update on GTI-2040 and GTI-2501*" will be given on Thursday, April 29 at 9:45 am in the session " *Updates on Oligonucleotide-Based Therapeutics in Clinical Development."*

Lorus will provide preclinical and clinical details on the progress of the Company's two clinical stage antisense drugs, GTI-2040 and GTI-2501. A number of recent preclinical studies have further validated the therapeutic application of these compounds, which target different subunits of the ribonucleotide reductase complex, an essential enzyme in *de novo* DNA synthesis and a novel malignancy determinant.

Clinical development of these compounds has expanded and includes a Phase II clinical trial with capecitabine in end-stage renal cell cancer, and the initiation of four of six US National Cancer Institute-sponsored clinical trials evaluating GTI-2040 in combination with a number of standard therapies across several cancer indications. Interim results of the renal cell cancer study were announced in January 2004. Unaudited data analysis indicated that more than half of the 21 evaluable patients in the study exhibited disease stabilization ranging up to eight months. Some tumor shrinkages were also observed. A Phase II/III registration clinical program for GTI-2040 in renal cell cancer is presently being designed.

In addition to GTI-2040, clinical development of GTI-2501 continues with the initiation of a Phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. Lorus' extensive preclinical antisense program which includes a number of potential therapeutic compounds focusing on several different genetic targets will also be discussed.

"The TIDES conference provides an opportunity for Lorus to profile its broad preclinical and clinical antisense program to leaders in the field of oligonucleotide technology. TIDES is an excellent forum for increasing industry exposure to our scientific and clinical progress at a time when GTI-2040 and GTI-2501 are progressing in their clinical development," said Dr. Jim Wright, chief executive officer of Lorus.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in a phase II clinical trials program and one phase III registration clinical

trial. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 20-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

For U.S. investor relations, please contact Tim Clemensen at 212-843-9337

Contacts:

Lorus Therapeutics Inc. Canadian Media Contact: US Media Contact
Corporate Communications Eliza Walsh Amy Banek
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: amy@mcipr.com

LORUS THERAPEUTICS ANNOUNCES INITIATION OF COLON CANCER TRIAL WITH GTI-2040 IN COOPERATION WITH THE U.S. NATIONAL CANCER INSTITUTE

-Novel drug combination enters clinical trial -

TSX: LOR
AMEX: LRP

TORONTO, CANADA, May 4, 2004 – Lorus Therapeutics Inc. ("Lorus") announced today the initiation of a clinical trial of GTI-2040 in a novel combination with oxaliplatin and capecitabine in patients with advanced unresectable colon cancer.

This new study is under the direction of Dr. Stephen Shibata at the City of Hope Comprehensive Cancer Center in Duarte California, together with Dr. Heinz-Joseph Lenz at the University of Southern California in Los Angeles, Dr. David Gandara at the Davis Cancer Center, University of California in Sacramento and Dr. Mark McNamara at the City of Hope Medical Group in Pasadena.

A key objective of this clinical study is to establish the optimal dose of this combination in colon cancer patients and the pharmacodynamic effects on cellular markers of anti-tumor activity when these agents are combined.

This trial is one of six clinical studies in a Phase II clinical program for GTI-2040 in combination with other agents and in various tumor types sponsored by the Cancer Therapy Evaluation Program (CTEP), a U.S. National Cancer Institute program that sponsors clinical trials of novel compounds to accelerate their development.

(more)

"We are delighted with the support of the CTEP program to extend GTI-2040 development to colon cancer," said Dr. Jim Wright, CEO of Lorus Therapeutics Inc. "Overlapping toxicities with common chemotherapy combinations can be a limiting factor in treating advanced diseases where single-agent therapy is rarely an option. GTI-2040 has good tolerability alone and in combination with other drugs in clinical studies to date, which makes it an encouraging opportunity for colon cancer therapy."

In preclinical studies, GTI-2040 has demonstrated reduction in the size of human adenocarcinoma tumors of the colon by 80 per cent when injected into mice compared to those in untreated mice using the standard mouse xenograft model. It has also demonstrated a broad spectrum of activity in vivo in preclinical models across many tumor types, and a 65 per cent to 95 per cent inhibition of lung metastases in two animal models.

In similar animal models, when combined with 5-FU (the active metabolite of capecitabine) or oxaliplatin, GTI-2040 has shown increased antitumor activity compared to either agent alone.

American Cancer Society data identifies colon cancer as the third most common cancer in both men and women with an estimated 106,370 new cases and 56,730 deaths expected to occur in 2004. While advances have come from earlier diagnosis, patients with metastatic colon cancer have achieved only modest improvement from advances in combination chemotherapies, which illustrates the need for new therapeutic combination strategies involving multiple targeted therapies.

GTI-2040 targets the R2 component of ribonucleotide reductase (RR), which is required for DNA synthesis, and is elevated in a wide range of tumor types where it may act as a signal molecule to enhance malignancy. It is predicted in this study that the mechanisms of cytotoxicity of capecitabine and of oxaliplatin, including inhibition of DNA repair, will be enhanced by this RR blockade in these colon cancer patients**.**

The chemotherapies combined with GTI-2040 in this trial, capecitabine and oxaliplatin, are FDA approved therapies for colon cancer, the former for first-line therapy and the latter in combination with 5-fluorouracil/Leucovorin.

About GTI-2040

GTI-2040 is a drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. R2 has also been described as a malignant determinant that is elevated in a wide range of tumors, and through deregulation can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential. GTI-2040 showed significant antitumor activity against many different human tumors in preclinical studies. In addition to a clinical trial in renal cell cancer, GTI-2040 is currently the subject of a Clinical Trial Agreement with the United States National Cancer Institute (NCI) under which GTI-2040 will be tested in combination chemotherapy in six different clinical trials. Five of these trials have now been initiated including treatment of metastatic breast cancer at the University of California, Davis Cancer Center; acute myeloid leukemia at the Ohio State University Medical Center, non-small cell lung cancer at Princess Margaret Hospital in Toronto, Ontario, a variety of solid tumors at the Institute of Drug development, Cancer Therapy and Research Center in San Antonio, Texas and the colon cancer clinical study announced today. The remaining clinical trial to be initiated with NCI sponsorship will investigate GTI-2040 in prostate cancer.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights,
commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Contacts:

Lorus Therapeutics Inc. Media Contact: **US Investor Relations**
Bruce Rowlands Eliza Walsh / Amy Banek Tim Clemensen
Senior Vice President Mansfield Communications Rubenstein Investor Relations
(416) 798-1200 ext. 338 (416) 599-0024 / (212) 370-5045 (212) 843-9337
browlands@lorusthera.com eliza@mcipr.com tim@rir1.com

LORUS ANNOUNCES DISCOVERY OF NOVEL LOW MOLECULAR WEIGHT COMPOUNDS WITH ANTICANCER AND ANTIBACTERIAL ACTIVITY

-Discovery to be announced at BioFinance conference in Toronto-

TSX: LOR
AMEX: LRP

TORONTO, CANADA, May 12, 2004 – Lorus Therapeutics Inc. ("Lorus") today announced the discovery of novel low molecular weight compounds with anticancer and antibacterial activity. The finding comes after three years of research by Lorus scientists through a small molecule discovery program. Lorus subsequently signed a collaboration agreement with the University of Toronto to provide a further development and delivery strategy for the compounds.

"Given the need for effective anticancer therapeutics and the growing concern over the development of multi-drug resistant bacteria, we are very pleased with the results obtained in this discovery program. There is great potential value in compounds that have these dual properties, so we intend to aggressively move this program forward," said Dr. Jim Wright chief executive officer of Lorus.

The development strategy will be partially funded by a grant awarded to Lorus and the University of Toronto from the Natural Sciences and Engineering Research Council of Canada / Collaborative Research and Development (NSERC/CRD), titled "*Development of Polymeric Delivery Systems for a Novel Series of Hydrophobic Therapeutic Agents,*" and will be performed in collaboration with Dr. Christine Allen, Department of Pharmaceutical Sciences at the University of Toronto.

"The collaboration brings together two groups of scientists with complementary expertise and provides an exciting opportunity for our nanotechnology to be utilized for the delivery of a promising series of highly potent agents," said Dr. Allen.

(more)

The anti-proliferative properties of the newly discovered compounds were corroborated in an *in vitro* anticancer screen provided by the DTP (Developmental Therapeutics Program) at the US National Cancer Institute. The compounds exhibited *in vivo* activity in animal models of infections, and preliminary evaluation of their *in vivo* efficacy in a xenograft model of human colon adenocarcinoma showed potent anticancer activity.

Although these compounds exhibit wide spectrum anti-proliferative activity, no apparent acute or chronic toxicity was observed in preliminary animal tests.

The formal research agreement with the University of Toronto to optimize a drug delivery system focuses on the synthesis and characterization of novel structural-based formulations specifically

designed for a number of lead compounds identified by Lorus as having anticancer and antibacterial activity. The collaboration will evaluate the *in vivo* pharmacokinetics and biodistribution of the formulated compounds as well as efficacy in animal models of human disease.

Results of *in vitro* and *in vivo* studies by Lorus scientists support the further development of these compounds as therapeutics for cancer and infectious disease. Of particular interest were compounds that inhibited the growth of several human tumor cell lines including hepatocellular carcinoma, pancreatic carcinoma, ovarian carcinoma, breast adenocarcinoma and metastatic melanoma. In addition, these compounds demonstrated activity against multi-drug resistant bacteria, which are responsible for a number of life-threatening infections in hospitalized and immune-compromised individuals.

Lorus to Present at the BioFinance 2004 Conference in Toronto

Lorus also announced that Dr. Aiping Young, chief operating officer of Lorus, will present a corporate overview of Lorus today at 2:30 p.m. at the BioFinance 2004 Conference in Toronto, including an announcement of the new anticancer/antibacterial small molecule technology. The conference is being held from May 11 – 13, 2004 at the Marriott Eaton Centre Hotel in Toronto, Ontario.

The conference brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

Contacts:

Lorus Therapeutics Inc. Media Contact: **US Investor Relations**
Bruce Rowlands Eliza Walsh / Amy Banek Tim Clemensen
Senior Vice President Mansfield Communications Rubenstein Investor Relations
(416) 798-1200 ext. 338 (416) 599-0024 / (212) 370-5045 (212) 843-9337
browlands@lorusthera.com eliza@mcipr.com tim@rir1.com

LORUS TO PRESENT AT THE RODMAN & RENSHAW TECHVEST GLOBAL HEALTHCARE CONFERENCE

-Live presentation to be webcast-

TSX: LOR
AMEX: LRP

TORONTO, CANADA, May 13, 2004 – Lorus Therapeutics Inc. ("Lorus") will be presenting at the Rodman & Renshaw Techvest Healthcare Conference on May 12-14, 2004 at Claridge's Hotel in London, UK. Dr. Jim Wright, president and CEO of Lorus, will present a comprehensive review of Lorus' oncology pipeline on May 13th.

The live presentation will be webcast, and a recording will be made available following the event. Presentations will be archived and available after the conference for a period of 90 days. The webcast and recording will be accessible through Lorus' website, located at www.lorusthera.com. To access the live webcasts, please log on to Lorus' site prior to the presentation to register and download any necessary audio software.

The Rodman & Renshaw conference brings together institutional investors, venture capitalists, corporate executives, business development officers and scientists to network and investigate different healthcare areas and issues. Areas of investigation at the conference will include infectious diseases, cardiovascular diseases, medical devices, CNS (Central Nervous System), oncology, drug delivery, specialty pharmaceuticals, gene therapy and therapeutic vaccines.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product

development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

-30-

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
Tel: (416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Pereina Choudhury / Amy Banek
Mansfield Communications
Tel: (416) 599-0024 / (212) 370-5045
pereina@mcipr.com/amy@mcipr.com

US Media Contact
Tim Clemensen
Rubenstein Investor Relations
Tel: (212) 843-9337
tim@rir1.com

LORUS THERAPEUTICS ALLOWED EUROPEAN PATENT TO PROTECT UNIQUE TUMOR SUPPRESSOR

TSX: LOR
AMEX: LRP

TORONTO, CANADA, June 1, 2004 – Lorus Therapeutics Inc. ("Lorus") announced today that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the European Patent Office for its discovery of a gene, which suppresses the growth of malignant tumors.

The patent titled, *'Suppression of Malignancy Utilizing Ribonucleotide Reductase R1,'* protects an innovative approach to inhibiting tumor growth in mammals, including humans. Using a vector delivery system, a tool of gene therapy, the tumor suppressor gene sequence is delivered to cancer cells and the resulting expression of the gene inhibits tumor growth. Preclinical studies demonstrated markedly suppressed tumor growth. The gene can also be delivered with virus vectors to tumor cells, where it was shown to be a very effective antitumor agent.

The European patent follows previous patents issued by both the United States Patent Office and the Australian Patent Office.

"The discovery of a gene that has the ability to suppress malignant growth is an important achievement for Lorus, and we are working vigorously to determine how this discovery can best be developed for the benefit of cancer patients," said Dr. Jim A. Wright, chief executive officer, Lorus. "Gene therapy is an exciting cutting-edge area of research and represents Lorus' fourth core technology platform under development."

(more)

Dr. Wright added: “The strategic diversification of our technology pipeline, which includes antisense, immunotherapy, small molecules and our tumor suppression gene, demonstrates Lorus’ commitment and unique approach to developing cancer therapies. This recent European patent allowance contributes to our strong global intellectual property portfolio, an important strategy for enhancing the value of our company.”

About Gene Therapy

Gene therapy is a novel approach employed to reverse diseases caused by genetic damage, such as cancer, which is based on modifying the expression of genes in damaged cells by, for example, delivering new functional genes to these cells which replace the genes in damaged cells. The identification of genes that are capable of reversing disease characteristics is of fundamental importance to gene therapy strategies.

Techniques are being developed for delivering genetic material to the appropriate cells in a way that is specific, efficient and safe. Gene delivery vehicles called vectors enable disease-related genes to be delivered to cells. A vector can be a disabled virus that cannot reproduce and cause disease, but that can act as a delivery mechanism to transport the gene to the target cell. Once the gene is inside the cell and is expressed, it can function to restore the patient’s health.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus’ goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company’s ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company’s ability to attract and retain business partners and key personnel, future levels of government funding, the Company’s ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company’s ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.’s press releases are available through the Company’s Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc. Media Contacts: **US Investor Relations**
Bruce Rowlands Pereina Choudhury / Amy Banek Tim Clemensen
Senior Vice President Mansfield Communications Rubenstein Investor Relations
(416) 798-1200 ext. 338 (416) 599-0024 / (212) 370-5045 (212) 843-9337
browlands@lorusthera.com pereina@mcipr.com/amy@mcipr.com tim@rir1.com

LORUS THERAPEUTICS PARTICIPATES AT THE 2004 ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

TSX: LOR
AMEX: LRP

TORONTO, CANADA, JUNE 4, 2004 – Lorus Therapeutics Inc. ("Lorus") announced today that it is participating at the American Society of Clinical Oncology (ASCO) annual meeting, June 5th to June 8th 2004, in New Orleans. At the conference, Lorus will provide data on two of its lead drugs, Virulizin(R) and GTI-2040.

Virulizin(R), Lorus' lead immunotherapy drug, currently in a Phase III registration clinical trial in North America and Europe for the treatment of advanced pancreatic cancer, is the subject of an abstract titled, "*Stimulation of Natural Killer (NK) Cell and Macrophage Infiltration in Pancreatic Cancer with Virulizin (V), an Immunotherapeutic Agent."*

The abstract, which is published in the meeting proceedings, summarizes preclinical studies using Virulizin (R) as an anticancer treatment. These studies supported a mechanism of action through enhanced immune cell activity, including Natural Killer (NK) cell function, across a number of cancer types including pancreatic cancer.

Recent preclinical studies demonstrate that NK cells infiltrate tumors following Virulizin (R) treatment. It is believed that low NK cell activity may be a risk factor for cancer or cancer spread, and a negative prognostic indicator in pancreatic cancer. Therefore, a drug that stimulates NK cell activity has the potential to be a valuable anticancer tool. In addition to primary and secondary endpoints, such as survival and clinical benefit, the current Phase III clinical trial will also examine NK cell function and other immune parameters as potential biologic markers of therapeutic response.

(more)

This data presentation on Virulizin(R) will also be given by Lorus' clinical team at the company's exhibitor booth. Additionally, the team will discuss the findings and the status of Virulizin(R) currently in a Phase III clinical trial and will share the progress on GTI-2040, a Phase II clinical stage compound under development by Lorus for the treatment of a variety of different cancer indications.

"The ASCO conference provides Lorus the opportunity to profile and share the significant advancements that we have made in the drug development progress of our clinical and preclinical programs," said Dr. Jim A. Wright, chief executive officer, Lorus. "The conference affords us the opportunity to engage in constructive dialogue regarding our programs with leading scientists and oncologists."

The ASCO annual conference is an important event in clinical oncology worldwide, attracting researchers, clinicians and members of the pharmaceutical industry. The conference provides oncology professionals with the most current information on recent developments in cancer research, prevention, and treatment.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com .

(30)

Contacts:
Lorus Therapeutics Inc. Media Contacts: **US Investor Relations**
Bruce Rowlands Pereina Choudhury / Amy Banek Tim Clemensen
Senior Vice President Mansfield Communications Rubenstein Investor Relations
(416) 798-1200 ext. 338 (416) 599-0024 / (212) 370-5045 (212) 843-9337
browlands@lorusthera.com pereina@mcipr.com/amy@mcipr.com tim@rir1.com

LORUS THERAPEUTICS INC. PRESENTS PROGRESS IN ITS PRODUCT DEVELOPMENT PROGRAMS AT BIO 2004

TSX: LOR
AMEX: LRP

TORONTO, CANADA, JUNE 7, 2004 – Lorus Therapeutics Inc. ("Lorus") announced today that it is participating and presenting at the BIO 2004 Annual International Convention, June 6th to June 9th 2004, in San Francisco, California.

Dr. Jim A. Wright, president and chief executive officer, Lorus will provide an overview of the company's business strategy and product development programs at BIO 2004 on Monday June 7th, 2004, at 4:00 PM in Room B.

BIO 2004 Annual International Convention is one of the world's largest biotechnology conferences with more than 60 countries represented at this year's San Francisco convention. The convention provides Lorus with the opportunity to share its clinical and preclinical progress with a distinguished international audience comprised of scientists, clinicians, investors and colleagues from the biotechnology community and pharmaceutical industry worldwide.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

(more)

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited

to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com .

Contacts:

Lorus Therapeutics Inc. Media Contact: **US Investor Relations**
Bruce Rowlands Eliza Walsh / Amy Banek Tim Clemensen
Senior Vice President Mansfield Communications Rubenstein Investor Relations
(416) 798-1200 ext. 338 (416) 599-0024 / (212) 370-5045 (212) 843-9337
browlands@lorusthera.com eliza@mcipr.com tim@rir1.com

LORUS THERAPEUTICS ACHIEVES FULL PATIENT ENROLLMENT IN VIRULIZIN® PHASE III REGISTRATION CLINICAL TRIAL

- Initial enrollment target of 400 exceeded -

TSX: LOR
AMEX: LRP

TORONTO, CANADA, June 17, 2004 – Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer today announced full enrollment of the company's Phase III FDA registration clinical trial of Virulizin(R) in combination with gemcitabine for the treatment of advanced pancreatic cancer. Over 400 patients have been enrolled into the study globally, exceeding the original target enrollment. Study sites are located in North America, South America, Europe and Russia.

This study compares the efficacy and safety of Virulizin(R) when combined with gemcitabine versus a placebo combined with gemcitabine in patients with locally advanced or metastatic pancreatic cancer. The primary efficacy endpoint is overall survival, while secondary endpoints include progression of symptoms of pain, deterioration of performance status and weight loss. Additionally, the activity of Natural Killer (NK) cells is evaluated throughout the study. The correlation between NK cell activity profiles and clinical outcome will be assessed. Virulizin(R) has been granted fast track status, orphan drug status and a special protocol assessment by the U.S. Food and Drug Administration (FDA) in advanced pancreatic cancer.

According to the study protocol requirement for follow-up, database lock and data analysis, the results of the study are anticipated for late 2005. This clinical study report will be pivotal in the application for marketing approval for Virulizin(R), which is planned for submission to the (FDA) in the first half of 2006.

(more)

"This is a significant milestone in the clinical development process of Virulizin(R) and Lorus is encouraged to see that the target has been achieved earlier than originally projected," said Dr. Jim Wright, CEO of Lorus. "This study was designed to examine Virulizin(R) in both the first line setting and also in the second line treatment setting in combination with 5FU."

Virulizin(R) is a novel immunotherapy that stimulates a patient's innate immune system through the activation of macrophages and the infiltration of NK cells into tumors. Evidence of clinical response was demonstrated in Phase II clinical studies of Virulizin(R) as a monotherapy in

advanced pancreatic cancer. Median survival compared favorably with single-agent chemotherapy trials, and endpoints of quality of life, pain and performance status were maintained or improved during the first four to eight weeks of treatment. Importantly, in contrast to most standard chemotherapeutic drugs, Virulizin(R) was well tolerated with no significant systemic toxicity.

Preclinical studies have demonstrated that Virulizin(R) activates macrophages and NK cells, produces significant reduction in tumor growth and increases survival across a broad range of animal xenograph models of human carcinoma.

In a gemcitabine-resistant pancreatic tumor model in mice, treatment with Virulizin (R) was associated with a delay in tumor growth and a significant reduction in tumor size compared to controls. Pharmacologic studies in healthy volunteers, as well as from cancer patients, suggest that peripheral blood monocytes, display a significantly enhanced capacity to kill tumor cell targets when stimulated with Virulizin(R).

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:

Lorus Therapeutics Inc. Media Contact: **US Investor Relations**
Bruce Rowlands Eliza Walsh / Amy Banek Tim Clemensen
Senior Vice President Mansfield Communications Rubenstein Investor Relations
(416) 798-1200 ext. 338 (416) 599-0024 / (212) 370-5045 (212) 843-9337
browlands@lorusthera.com eliza@mcipr.com tim@rir1.com

LORUS CEO DR. JIM WRIGHT TO RING OPENING BELL ON THE AMERICAN STOCK EXCHANGE ON FRIDAY JUNE 18, 2004

TSX: LOR
AMEX: LRP

TORONTO, CANADA, June 17, 2004 – Lorus Therapeutics Inc. (Lorus) announced today that Dr. Jim Wright, CEO of Lorus Therapeutics has been invited to ring the opening bell for trading at the American Stock Exchange (Amex) on June 18, 2004. Bruce Rowlands, senior vice-president, will also attend the ceremony.

As part of the welcoming ceremony, Amex will conduct an interview with Lorus which will be available via web cast on the Amex website, www.amex.com, on June 21.

"It is an honor to participate in the bell ringing ceremony at the American Stock Exchange," said Dr. Wright. "Our listing on the Amex will allow broader investor participation in Lorus as we move forward in registration with our lead anticancer drug, Virulizin(R)."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

Webcast Alert:
Lorus Therapeutics (Amex:LRP) Presentation at
American Stock Exchange Annual Online Healthcare & Biotech Investor Conference

What: Lorus Therapeutics Presentation at the American Stock Exchange and Amex Online Alliance Online Conference

When: June 22, 2004 at **10:30 AM**

Where: http://www.vcall.com/CEPage.asp?ID=88397

How: Live over the Internet --- simply log on to the web address above.

Contact: **Bruce Rowlands (416) 707-8257**

If you are unable to participate during the live webcast, the presentation will be archived at www.vcallconferences.com and http://www.lorusthera.com.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin$^{(R)}$ is a registered trademark of Lorus Therapeutics Inc.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

For a complete agenda of the American Stock Exchange and Amex IR Alliance Online Conference, please visit http://www.vcallconferences.com/conferences/AMEX/0622-29-2004/index.asp?ID=88206.

About American Stock Exchange

The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 138 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks.

Minimum requirements to listen to broadcast: Windows Media Player software, downloadable free from http://microsoft.com/windows/windowsmedia/EN/default.asp and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, please send an email to webmaster@vcall.com.

Contacts:
Lorus Therapeutics Inc. Media Contacts: **US Investor Relations**
Bruce Rowlands Eliza Walsh / Amy Banek Tim Clemensen
Senior Vice President Mansfield Communications Rubenstein Investor Relations
(416) 798-1200 ext. 338 (416) 599-0024 / (212) 370-5045 (212) 843-9337
browlands@lorusthera.com eliza@mcipr.com/amy@mcipr.com tim@rir1.com

LORUS THERAPEUTICS TO BE A SPONSOR OF THE 6TH ANNUAL LUSTGARTEN FOUNDATION SCIENTIFIC CONFERENCE

- Conference co-sponsored by the American Association for Cancer Research (AACR) and the University of California at San Francisco -

TSX: LOR
AMEX: LRP

TORONTO, June 24, 2004 – Lorus Therapeutics Inc. ("Lorus") announced today that it will be an education sponsor of the 6th Annual Lustgarten Foundation Scientific Conference being held in San Francisco, CA, from June 25-26, 2004.

The conference targets clinical researchers, oncologists, post-doctorate fellows and allied medical professionals worldwide. The Lustgarten Foundation for Pancreatic Cancer Research is the largest private foundation exclusively dedicated to supporting pancreatic cancer research.

An abstract entitled, "Virulizin(R) Induces Antitumor Activity Through Activation and Interaction of Innate Immunity" has been accepted for presentation at the conference and will be published in the meeting proceedings.

The data being presented are the culmination of a preclinical research program that revealed key elements of the molecular and cellular mechanism of action in Virulizin(R), Lorus' lead anticancer drug candidate.

(more)

Virulizin(R) was shown to stimulate major components of the immune system as observed by activation of macrophages, increased expression of inflammatory cytokines and expansion and activation of natural killer (NK) cells. These events led to increased infiltration of macrophages and NK cells into tumors which coincided with increased markers for programmed cell death within the tumors— hallmarks of an antitumor immune response.

"The Lustgarten Conference serves a very important purpose in the development of treatments for pancreatic cancer," said Dr. Jim Wright, chief executive officer of Lorus. "It provides a forum for the exchange of ideas, research, progress and dialogue for those in the scientific community seeking to develop, improve and advance therapies that will best treat pancreatic cancer patients."

Lorus' lead immunotherapeutic drug, Virulizin(R) is currently in a fully enrolled pivotal Phase III registration-clinical trial in North America, South America, Europe, and Russia for the treatment of advanced pancreatic cancer. It has been awarded orphan drug status, fast track status and a special protocol assessment from the United States Food and Drug Administration.

The Lustgarten Foundation concentrates its efforts on helping the scientific community work towards finding a cure for pancreatic cancer. The Foundation has awarded $9 million in support of promising pancreatic research and has sponsored four international scientific meetings at leading institutions. The Foundation also provides patient information through the dissemination of handbooks and a comprehensive web site, and promotes public awareness of this devastating disease through a public service announcement campaign featuring former President Jimmy Carter, who also serves as honorary chairman of the Foundation's corporate advisory board.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc .

Forward-Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com .

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS EXPANDS PROSTATE CANCER TRIAL OF GTI-2501 WITH DOCETAXEL TO TWO ADDITIONAL SITES IN CANADA

TSX: LOR
AMEX: LRP

TORONTO, CANADA, July 8, 2004 – Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer today announced that it has expanded its Hormone Refractory Prostate Cancer (HRPC) trial to two additional sites in Canada. The combination of GTI-2501 and docetaxel in this clinical trial is being investigated in patients with asymptomatic or symptomatic HRPC where disease progression is uncontrolled.

The principal investigators at the new sites will be Dr. Peter Venner, Director of the Division of Medical Oncology at the Cross Cancer Institute, Edmonton, Alberta, and Dr. Scott Ernst, Associate Professor, Division of Medical Oncology, at the London Regional Cancer Centre, London, Ontario. Both are leading researchers in the field representing major centres for prostate cancer research in Canada and have contributed to many trials and publications in the treatment of this disease**.** Dr. Venner and Dr. Ernst will collaborate with Sunnybrook and Women's Health Centre in Toronto where the clinical trial has been ongoing under the direction of Dr. Scott Berry and Dr. Lawrence Klotz.

GTI-2501 is a novel investigational antisense drug which has shown a favorable safety profile in preclinical studies and in a phase I clinical trial. Initial testing has demonstrated strong antitumor activity in preclinical studies in prostate cancer and a variety of other tumor types. It is designed to exert its activity by specific downregulation of the R1 component of ribonucleotide reductase, an enzyme essential for DNA replication and cell proliferation which is upregulated in a variety of different tumors. Docetaxel is a chemotherapeutic agent extensively studied for the treatment of prostate cancer.

(more)

“Lorus is very pleased to extend its collaboration to additional sites in this clinical program, and is looking forward to the results that will come out of this promising clinical study of an unique combination of drugs for the treatment of hormone refractory prostate cancer,” said Dr Jim Wright, CEO of Lorus Therapeutics.

Prostate cancer is the most frequently diagnosed cancer in men, with over 230,110 new cases diagnosed in the United States each year, and 29,900 deaths, second only to lung cancer, according to the 2004 estimates recently released by the American Cancer Society.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company’s ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company’s ability to attract and retain business partners and key personnel, future levels of government funding, the Company’s ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company’s ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.’s press releases are available through the Company’s Internet site: http://www.lorusthera.com.

(30)

Contacts:

Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

TSX: LOR
AMEX: LRP

LORUS THERAPEUTICS REPORTS YEAR END RESULTS FOR FISCAL YEAR 2004

TORONTO, CANADA – **July 23, 2004** – Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today reported financial results for the year ended May 31, 2004. Unless specified otherwise, all amounts are in Canadian dollars.

YEAR 2004 AND SUBSEQUENT HIGHLIGHTS

- In June 2004 achieved full patient enrollment with over 400 patients enrolled into the pivotal Phase III FDA registration clinical trial of Lorus' lead immunotherapeutic drug Virulizin$^{(R)}$ for the treatment of advanced pancreatic cancer. The study exceeded the original target enrollment and at an earlier date.
- Entered into a worldwide exclusive out-licensing agreement with Cyclacel Limited of the UK for NC381 and a library of clotrimazole analogs.
- Initiated five clinical trials in collaboration with the US National Cancer Institute (NCI) for a phase II clinical program of GTI-2040 in patients with Acute Myeloid Leukemia (AML), breast cancer, non-small cell lung cancer, solid tumors and advanced unresectable colon cancer.
- Initiated a phase II clinical trial in hormone refractory prostate cancer patients with GTI-2501, one of the Company's lead antisense drug candidates at three prominent Canadian cancer centers.
- After about three years of research, discovered novel low molecular weight compounds with anticancer and antibacterial activities. Lorus subsequently signed a collaboration agreement with the University of Toronto to provide further development for the compounds.
- Interim data was analyzed from the phase II clinical trial of GTI-2040 in combination with capecitabine for patients with advanced end-stage renal cell carcinoma who had failed two or more prior therapies before entering the study, exhibited extensive metastases, and were representative of a population with very poor prognostic outcome. The data showed that more than half of the 21 evaluable patients in this study exhibited disease stabilization, ranging up to eight months. Tumor shrinkages of index tumors compared to baseline measurements were also observed in some patients.
- To increase Company exposure to US investors, obtained approval to list on the American Stock Exchange and commenced trading on the exchange on February 23, 2004.

“In 2004, Lorus continued to create shareholder value as it achieved several significant milestones in the fight against cancer,” said Dr. Jim Wright, CEO of Lorus. “Both reaching full enrollment in the expanded Virulizin(R) Phase III clinical trial earlier than anticipated, as well as the expansion and initiation of the GTI-2040 and GTI-2501 Phase II clinical trials demonstrate Lorus’ commitment to bringing novel, high-safety and effective cancer therapies to a hard-to-treat patient population. Lorus’ significant achievements in 2004 have necessitated increased spending, however in 2005 we anticipate a decrease in our spending as our major clinical trial with Virulizin(R) is underway and there will be no further initiation costs incurred in 2005. In the next fiscal year, the Company will focus on arrangements for the commercialization of Virulizin(R) and on partnerships and further development of lead technologies. ”

Net loss for the year ended May 31, 2004 totaled $30,301,000 ($0.18 per share) compared to a loss of $16,634,000 ($0.12 per share) for the previous fiscal year. The Virulizin(R) Phase III clinical trial expansion that resulted in full enrollment in June 2004, the increased manufacturing and compliance activities and the procurement of drug supply for the U.S. NCI-sponsored Phase II clinical trial programs for GTI-2040 contributed to the increase for the year ended May 31, 2004.

Product, royalty and license revenue was $608,000 for the year ended May 31, 2004 compared to $66,000 for the previous fiscal year. Included in revenue is an initial license fee of $546,000 received from Cyclacel Limited in connection with the out-licensing of Lorus’ small molecule program.

Research and development expenses for the year ended May 31, 2004 increased to $26,785,000 from $12,550,000 in the prior year. The increase in expenditures on research and development activities relates primarily to higher clinical trial and regulatory expenditures for the continuation of the expanded pivotal Phase III clinical trial of Virulizin(R) for the treatment of advanced pancreatic cancer and the upfront procurement of the GTI-2040 drug for the US NCI-sponsored Phase II clinical trial programs initiated during 2004.

Consolidated Statements of Loss and Deficit
For the Years Ended May 31

(Amounts in 000's except for per common share data)	Year Ended May 31		
(Canadian Dollars)	**2004**	2003	2002
Revenue	**$ 608**	$ 66	$ -
	608	66	-
Operating expenses			
Cost of sales	**28**	55	-
Research and development	**26,785**	12,550	8,659
General and administrative	**4,915**	4,290	4,867
Depreciation and amortization	**420**	960	1,956
Operating expenses	**32,148**	17,855	15,482
Interest and other income	**(1,239)**	(1,155)	(1,995)
Loss for the period	**30,301**	16,634	13,487
Deficit, beginning of period	**91,503**	74,869	61,382
Deficit, end of period	**$ 121,804**	$ 91,503	$ 74,869
Basic and diluted loss per common share	**$ 0.18**	$ 0.12	$ 0.09
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per share	**171,628**	144,590	143,480

Selected Balance Sheet Information
As at May 31

(Amounts in 000's Canadian Dollars)		**2004**		2003
Cash, cash equivalents and short-term investments	**$**	**26,728**	$	25,124
Prepaid expenses and amounts receivable		**1,697**		1,104
Total current assets		**28,425**		26,228
Fixed assets		**1,471**		1,507
Goodwill		**606**		606
Acquired research and development		**3,922**		5,669
Accounts payable and accrued liabilities		**5,825**		5,360
Share capital		**150,403**		120,398
Deficit accumulated during development stage		**(121,804)**		(91,503)

Media, members of the financial community and shareholders are invited to listen to the Company's quarterly earnings presentation through an audio webcast on the company's website at www.lorusthera.com on Friday, July 23, 2004.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical developments and marketing may be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin(R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS THERAPEUTICS INC. PRESENTS VIRULIZIN(R) AT INTERNATIONAL IMMUNOLOGY CONFERENCE

-Presentation outlines details of how Virulizin(R) stimulates an antitumor immune response-

TSX: LOR
AMEX: LRP

TORONTO, CANADA, July 23, 2004 – Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, will be presenting at the joint 12th International Congress of Immunology (ICI) and 4th Annual Conference of the Federation of Clinical Immunology Societies (FOCIS) to be held in Montreal, Canada, July 18-23, 2004.

A study entitled "*Virulizin(R), a novel biological response modifier, activates NK cells and induces antitumor activity* **"** has been accepted for presentation. The study will also be published as an abstract in the meeting abstract book and in a supplement to the *Clinical Investigative Medicine Journal*. [Abstract Number (1212AM) and Publication Number (Th53.262)].

Virulizin$^{\dot{O}}$ is a novel biological response modifier that has demonstrated strong antitumor efficacy and an excellent safety profile in previous studies. Currently, Virulizin(R) is being evaluated for efficacy in a pivotal Phase III clinical trial against pancreatic cancer and is Lorus' most clinically advanced anticancer therapeutic. The investigation accepted for presentation outlines the recent preclinical studies that have identified critical cellular and molecular details of how Virulizin(R) stimulates an antitumor immune response.

(more)

The presentation will cover a number of *in vivo* and *in vitro* experiments that demonstrate the involvement of specialized immune cells, called NK cells, in the antitumor response elicited by Virulizin(R). Virulizin(R) treatment results in expansion and activation of NK cells in the spleen with a subsequent increase in NK cell infiltration into tumors. In NK cell-depleted animals, Virulizin(R)-mediated antitumor response is significantly diminished.

"In the last two years, our understanding of how Virulizin(R) acts as an antitumor agent has progressed significantly and we are pleased with the opportunity to present our data at an international meeting of this caliber," said Dr. Jim Wright, CEO of Lorus Therapeutics. "ICI and FOCIS represent the leading edge of immunology research both from a basic science and clinical perspective."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS THERAPEUTICS INC. TO PRESENT RESULTS OF NOVEL ANTICANCER SMALL MOLECULE STUDIES

-Lead compound suppressed the growth of most cancer cell types-

TSX: LOR
AMEX: LRP

TORONTO, CANADA, August 9, 2004 – Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, will introduce a novel series of anticancer small molecules at the IBC's 9th Annual World Congress Drug Discovery Technology (R) 2004 to be held in Boston, from August 8-13, 2004. An abstract entitled "*Anti-proliferative activity of novel aryl-imidazoles and their possible mechanism of action"* has been accepted for presentation and will be published in the meeting proceedings.

This novel series of compounds has demonstrated potent anti-proliferative activity against a variety of human cancer cell types. Promising cancer cell growth inhibition was demonstrated in the National Cancer Institute's (NCI) 60-cell line tumor panel. Moreover, in animal models of human colon cancer and liver cancer, treatment with several leading compounds resulted in significant inhibition of tumor growth.

Results of studies conducted to investigate the mechanism of action of this series of compounds will be presented at the meeting, specifically focusing on a lead compound termed ML-220. ML-220 suppressed the growth of most cancer cell types. Studies using HT-29 colon cancer cells demonstrated the alteration of the cell cycle by ML-220 through induction of partially reversible arrest in the G0/G1 phase.

(more)

The subcellular localization of ML-220 in cancer cells was investigated by fluorescent microscopy and demonstrated that ML-220 localizes in the perinuclear area closely associated with the endoplasmic reticulum (ER), subcellular network of membranes responsible for manufacture and transfer of membranes and secretory proteins. In addition, ML-220 was found to be an inhibitor of kinases, enzymes involved in many cell-signaling pathways. Altered expression of these enzymes is often associated with abnormal cell growth and development of tumors.

Consequently, targeting cancer-related kinase activity presents novel opportunities for the development of new cancer therapies designed to be less toxic than conventional chemotherapeutic drugs. The subcellular distribution and morphological changes induced by these compounds in cancer cells, as well as their selective pattern of kinase inhibition suggest that they target novel mechanisms of signal transduction.

ML-220 and related derivatives have potential as therapeutic agents for the treatment of human cancer. Further studies are currently in progress to identify the precise mechanisms.

“In a continued effort to expand its platform technologies, Lorus initiated a small-molecule discovery program based on a novel chemical scaffold. It is encouraging to see that a number of molecules from this project demonstrate activity as anticancer agents, both in cell culture studies and in animal models of human cancer,” said Dr. Jim Wright, chief executive officer of Lorus.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc .

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company’s ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company’s ability to attract and retain business partners and key personnel, future levels of government funding, the Company’s ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company’s ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.’s press releases are available through the Company’s Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

POSITIVE CLINICAL RESULTS OBSERVED IN LORUS THERAPEUTICS' CLINICAL TRIAL OF GTI-2040

-Clinical findings from the dose escalation stage of the study -

TSX: LOR
AMEX: LRP

TORONTO, CANADA, August 13, 2004 – Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced findings from the dose escalation stage of the ongoing Phase II clinical trial of its novel antisense drug, GTI-2040 combined with capecitabine in metastatic kidney cancer.

On behalf of participating investigators at seven clinical study sites in the United States, Dr. Apurva Desai, an oncology investigator at the University of Chicago, will present the clinical findings at the First International Congress on Kidney and Bladder Cancer in Orlando, Florida. These findings demonstrated that GTI-2040 is well tolerated in combination with capecitabine, with no reduction in the starting capecitabine dose required, up to and including the target GTI-2040 dose that was previously established as a monotherapy in a Phase I clinical investigation.

The Phase II efficacy stage of this clinical study is ongoing and nearing completion. Lorus reported promising interim clinical results in a news release dated January 12, 2004.

"We are pleased that GTI-2040, in combination with the chemotherapeutic agent capecitabine, is well tolerated even at the maximum target dose established as a single agent. This supports our strategy of developing novel anticancer agents that exhibit minimal additional toxicity when combined with traditional chemotherapies," said Dr. Jim Wright, CEO of Lorus.

(more)

GTI-2040 is an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase, an activity that is essential for DNA synthesis. R2 is frequently over-expressed in cancer cells, and has been shown to cooperate with a variety of oncogenes to increase the tumorigenic and malignant potential of cancer cells.

The presentation also summarizes preclinical data from human renal cell carcinoma experiments, which demonstrated greater reduction in tumor size with combination GTI-2040 and 5-FU, the active component of capecitabine, compared to either agent alone, in support of the rationale for this clinical program.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of seven clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc .

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

TSX: LOR
AMEX: LRP

TORONTO, CANADA, September 7, 2004 – Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, is pleased to announce the appointment of Paul J. Van Damme as chief financial officer, Lorus Therapeutics Inc., effective immediately. Mr. Van Damme has more than 20 years of financial strategy and operations experience in the biotechnology sector and in other industries.

"We are very pleased to welcome Paul to Lorus Therapeutics. He is an accomplished executive whose wealth of business experience and knowledge of biotechnology will be an asset to Lorus as we continue to grow and develop our anticancer drugs towards commercialization," said Jim Wright, CEO of Lorus.

Mr. Van Damme began his biotechnology career at GlycoDesign Inc, as vice president of finance. He then went on to apply his skills as senior vice president, finance and chief financial officer of Allelix Biopharmaceuticals Inc., where he was responsible for all aspects of financial management and investor relations. He participated in the sale of the company to NPS Pharmaceuticals Inc., of Salt Lake City, USA. Mr. Van Damme has also held senior finance positions in several other public companies in diversified industries.

A chartered accountant, Mr. Van Damme also holds an MBA and a B.Comm from the University of Toronto. He belongs to several professional associations including the Canadian Institute of Chartered Accountants and Financial Executives International.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or

in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin(R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS PUBLISHES RESULTS OF STUDIES EXAMINING THE MECHANISM BY WHICH VIRULIZIN (R) ACTS AS AN ANTITUMOR AGENT

-Role of natural killer cells examined-

TSX: LOR
AMEX: LRP

TORONTO, CANADA, September 23, 2004 – Scientists at Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, have published the results of experimental studies with Virulizin(R), the company's lead anticancer drug. The results currently appear online in an article entitled, " *NK cell activation and tumor infiltration are involved in the antitumor mechanism of Virulizin(R)* " in the electronic publication of *Cancer Immunology*, *Immunotherapy*, and will subsequently appear in the printed version of the journal later this month.

Previous preclinical studies demonstrated the antitumor efficacy of Virulizin(R) in human tumor models in mice and a critical role for specialized immune cells called macrophages in the antitumor mechanism of action. The current study, performed in collaboration with the Calcium Research Laboratory, Department of Medicine, McGill University, examined whether another subset of immune cells called natural killer cells (NK) are also involved in Virulizin(R) antitumor activity.

Examination of tumor tissues at the cellular level demonstrated that human tumors implanted into mice subsequently treated with Virulizin (R) had an increased number of macrophages and NK cells infiltrated directly into the tumor. The increase in NK cell infiltration occurred at an early stage of Virulizin(R) treatment and correlated with an early sign of increased tumor cell killing. Also observed was increased numbers of NK cells in the spleen, the tissue of origin for mature NK cells, and these NK cells isolated from spleen also exhibited increased capacity to kill tumor cells in vitro.

(more)

In NK deficient mice, the antitumor activity of Virulizin(R) was compromised, providing additional support to the proposal that NK cells are necessary for Virulizin(R) activity. Depletion of macrophages resulted in a loss of Virulizin Ò-induced NK cell infiltration into tumors, indicating that macrophages stimulate NK cell infiltration into tumors. These results strongly support a mechanism in which Virulizin(R) stimulates immune cells in a coordinated manner, such that they migrate to the tumor and destroy tumor cells.

"In recent years, the scientists at Lorus have produced a number of publications that provide consistent evidence for how Virulizin (R) acts as an antitumor agent. This latest publication adds a critical component to the cellular mechanism of action and sets the groundwork for ongoing molecular studies," said Dr. Jim Wright, chief executive officer of Lorus. "From a drug development perspective, a solid publication record in respected peer-reviewed scientific journals is an important element in gaining approval for Virulizin(R) from the US FDA."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS THERAPEUTICS PRESENTS AT ASIA'S LARGEST BIOTECHNOLOGY CONFERENCE

–Lorus to review progress of its extensive oncology pipeline–

TSX: LOR
AMEX: LRP

TORONTO, CANADA, September 28, 2004 – Lorus Therapeutics Inc. ("Lorus") announced today that the company's chief operating officer, Dr. Aiping Young, and director of business development, Germaine Gross, will attend the BioJapan conference in Tokyo, Japan. Dr. Young will present a comprehensive review of Lorus' oncology pipeline to the conference on September 30th.

BioJapan is Asia's largest biotechnology-related conference. The conference will include presentations from biotechnology representatives from over seven different countries. Participants will have the opportunity to investigate potential partnership opportunities, explore Japan's biotech clusters and meet with executives from other biotech companies looking to develop new international relationships.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS THERAPEUTICS TO PRESENT AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE

TSX: LOR
AMEX: LRP

TORONTO, CANADA, September 29, 2004 – Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, announced that Bruce Rowlands, senior vice-president, planning and public affairs, will present Lorus' preclinical and clinical oncology pipeline tomorrow at 3:00 p.m. at the UBS Global Life Sciences Conference being held at the Grand Hyatt Hotel in New York City.

The presentation will also be audio webcast via the www.ibb.ubs.com website. The audio transmission of the presentations will be available live and by replay. The replay of presentation will begin at 6:00 p.m. on September 30 and will be available until October 30, 2004.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual

information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS ENCOURAGED BY PHASE II INTERIM CLINICAL DATA PROVIDING EVIDENCE OF DISEASE STABILIZATIONS, TUMOR REDUCTIONS, AND A FAVOURABLE SAFETY PROFILE WITH GTI-2040 IN COMBINATION THERAPY IN ADVANCED RENAL CELL CARCINOMA

-Clinical investigators present findings at major international conference in Geneva -

TSX: LOR
AMEX: LRP

TORONTO, CANADA, September 30, 2004 – Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, announced it will present new clinical results today of a study in metastatic renal cell carcinoma with GTI-2040 in combination with capecitabine at a major international conference in Geneva, Switzerland.

The ENA meeting, a leading forum for presenting clinical oncology research, is organized jointly by the European Organization for Research and Treatment of Cancer (EORTC), United States National Cancer Institute (NCI), and American Association for Cancer Research (AACR).

In this clinical trial**,** GTI-2040, a novel oligonucleotide with specificity for the R2 component of ribonucleotide reductase that is elevated in renal cell carcinoma and many other cancers, was investigated in combination with capecitabine, an established chemotherapeutic agent that has also been studied in renal cell cancer.

Of 29 patients reported, including 25 evaluable for best response, all had advanced metastatic renal cell cancer that had either failed or was ineligible for standard therapies, and are representative of a population with very poor prognostic outcome.

(more)

Data presented from the ongoing clinical study reported that at the recommended Phase II dose, more than 50 per cent of patients with advanced metastatic renal cell carcinoma showed disease stabilization. Best tumor shrinkages included a 39 per cent reduction in a patient with a significant partial response and a 23 per cent reduction in a patient who had durable stabilization of disease of 10 months duration. Adverse events were consistent with those expected with the drug combination studied, and demonstrated that GTI-2040 is well tolerated when combined with a cytotoxic agent like capecitabine.

"Lorus Therapeutics is focused on developing anticancer drugs which complement the efficacy of more toxic chemotherapies without adding significant additional toxicity," said Dr Jim Wright, CEO of Lorus Therapeutics. "We were pleased with the mild side effect profile previously seen with GTI-2040 alone, and its suitability for combination treatment, as part of a program that will also include investigation of GTI-2040 in combination with interferon immunotherapy as first-line therapy."

The meeting presentation cited prior preclinical research on GTI-2040 combined with capecitabine in preclinical models which had demonstrated complementary activity of these agents in preventing and regressing growth of human kidney cancer tumor grafts.

The interim clinical study evaluation, under the lead authorship of Dr. Frank Torti of Wake-Forest University in Winston-Salem NC, was presented at the meeting by Dr. Apurva Desai of University of Chicago. It provides the first detailed analysis of safety and efficacy for this ongoing phase II clinical trial.

About GTI-2040

GTI-2040 is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. It has also been described as a malignant determinant that is elevated in a wide range of tumors, and through deregulation can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential. GTI-2040 showed significant antitumor activity against many different human tumors in preclinical studies. In addition to the clinical trial in renal cell cancer described above, GTI-2040 is currently the subject of a Clinical Trials Agreement with the United States National Cancer Institute (NCI) under which GTI-2040 will be tested in combination chemotherapy in six different clinical trials. Five of these trials have been initiated.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS THERAPEUTICS TO PRESENT AT LEADING BIOTECHNOLOGY CONFERENCES IN CANADA AND EUROPE

–Lorus to review progress of its extensive oncology pipeline–

TSX: LOR
AMEX: LRP

TORONTO, CANADA, October 6, 2004 – Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced that Bruce Rowlands, senior vice president, planning and public affairs, will present a comprehensive review of Lorus' oncology pipeline on October 7, 2004 at BioContact in Quebec City. Dr. Yoon Lee, director of research and development, and Germaine Gross, director of business development, will also be presenting the pipeline on October 11, 2004 at the BioPartnering Europe conference in London, England.

The BioContact conference, Canada's leading biopharmaceutical conference, provides a forum for participants in the global biotechnology industry to network and meet with representatives from more than 150 biopharmaceutical companies from across North America, Europe and Asia.

The 12th Annual BioPartnering Europe conference was initiated in 1993 between the U.S. Commercial Service and Technology Vision Group LLC to establish stronger relationships between North American and European biotechnology companies.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40 -F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

LORUS ANNOUNCES $15 MILLION CONVERTIBLE DEBENTURE FINANCING

TSX: LOR
AMEX: LRP

TORONTO, CANADA, October 7, 2004 – Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced the closing of the first tranche of a $15 million private placement of convertible secured debentures with The Erin Mills Investment Corporation (TEMIC). The proceeds of the private placement will be used to finance the Company's research and development and on-going operations.

Pursuant to the terms of the private placement, Lorus has issued to TEMIC a convertible debenture in the principal amount of $5 million maturing October 6, 2009. The debenture is convertible at the option of the holder at any time prior to maturity into common shares at a conversion price of $1.00 per common share. The conversion price represents a 33 per cent premium to the October 5, 2004 closing price on the Toronto Stock Exchange.

TEMIC has agreed to purchase two additional secured convertible debentures, each in the principal amount of $5 million, on each of January 14, 2005 and April 15, 2005, provided that an event of default has not occurred under any debentures held by TEMIC or a material adverse change has not occurred in the business and affairs of Lorus. The conversion price to convert these debentures into common shares will be equal to the greater of: (i) $1.00 and (ii) the 20-day weighted average trading price of the common shares on the Toronto Stock Exchange, less the discount permitted by the TSX.

(more)

The principal amount of the debentures is secured by a first charge over all of the assets of Lorus and bears interest at the rate of prime plus 1 per cent per annum, compounded monthly. Interest is payable monthly on the debentures in common shares until the price of Lorus' common shares on the TSX is equal to a 60-day weighted average trading price of $1.00 per share at which point, the interest is payable on a monthly basis in cash or in common shares, at the option of the holder. No further interest is payable on the debentures if the market price of Lorus' common shares on the TSX is equal to or exceeds a 60-day weighted average trading price of $1.75 per share.

Lorus has paid to TEMIC a fee of $600,000 plus 3,000,000 warrants (2,000,000 of which will be held in escrow exercisable into common shares) as consideration for entering into the transaction. In addition, Lorus has issued 1,000,000 warrants to purchase common shares to TEMIC also to be held in escrow. The warrants will be released from escrow to either Lorus for cancellation or TEMIC subject to the fulfillment of certain conditions. The exercise price of the warrants is $1.00 per common share and they expire 5 years from the date of issuance.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin (R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information form, annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.

(30)

Contacts:
Lorus Therapeutics Inc.
Bruce Rowlands
Senior Vice President
(416) 798-1200 ext. 338
browlands@lorusthera.com

Media Contact:
Eliza Walsh / Amy Banek
Mansfield Communications
(416) 599-0024 / (212) 370-5045
eliza@mcipr.com

US Investor Relations
Tim Clemensen
Rubenstein Investor Relations
(212) 843-9337
tim@rir1.com

TSX: LOR
AMEX: LRP

LORUS THERAPEUTICS REPORTS FIRST QUARTER RESULTS FOR FISCAL YEAR 2005

TORONTO, CANADA – **October 8, 2004** – Lorus Therapeutics Inc. ("Lorus") today reported financial results for the three months ended August 31, 2004. Unless specified otherwise, all amounts are in Canadian dollars.

JUNE 1, 2004 TO DATE HIGHLIGHTS

- In June 2004, Lorus achieved full patient enrollment with over 400 patients in the pivotal Phase III FDA registration clinical trial of Lorus' lead immunotherapeutic drug Virulizin(R) for the treatment of advanced pancreatic cancer. The number of patients enrolled exceeded the target and was achieved earlier than scheduled.
- On October 6, 2004, subsequent to the first quarter, Lorus entered into an agreement to raise proceeds of $14.4 million through the issuance of $15.0 million of secured convertible debentures. Lorus received $4.4 million on October 6, 2004 and will receive $5.0 million on January 14 and on April 15, 2005. The debentures will expire on October 6, 2009 and interest is at a rate of prime + 1% until Lorus' share price reaches $1.75 for 60 consecutive trading days, at which time interest will no longer accrue. The $5.0 million principal amount is convertible at the debenture holder's option into common shares of Lorus with an exercise price of $1.00. The $10.0 million principal amount issued thereafter is convertible at an exercise price equal to the greater of $1.00 per share and the twenty-day weighted average trading price of Lorus' shares less any discount permitted by the Toronto Stock Exchange. The agreement also provides for the issuance of up to 4 million warrants, with a term of five years, to buy common shares at a price per share of $1.00.
- Introduced a novel series of anticancer small molecules at the IBC's 9th Annual World Congress Drug Discovery Technology (R) 2004. This novel series of compounds has demonstrated potent anti-proliferative activity against a variety of human cancer cell types. Promising cancer cell growth inhibition was demonstrated in the National Cancer Institute's (NCI) 60-cell line tumor panel. Moreover, in animal models of human colon cancer and liver cancer, treatment with several leading compounds resulted in significant inhibition of tumor growth.
- Announced positive findings from the dose escalation stage of the ongoing Phase II clinical trial of our novel antisense drug, GTI-2040, combined with capecitabine in metastatic kidney cancer. These findings demonstrated that GTI-2040 is well tolerated in combination with capecitabine, with no reduction in the initial capecitabine dose required, up to and including the target GTI-2040 dose that was previously established as a monotherapy in a Phase I clinical investigation.
- Announced the expansion of the Phase II clinical trial using GTI-2501 to treat Hormone Refractory Prostate Cancer (HRPC) to two additional sites in Canada, the London Regional Cancer Centre in London, Ontario and the Cross Cancer Institute in Edmonton, Alberta. The combination of GTI-2501 and docetaxel in this clinical trial is being investigated in patients with asymptomatic or symptomatic HRPC where disease progression is uncontrolled.

- Additions to Lorus' management team include a new Chief Financial Officer, Paul Van Damme, who is an experienced biotechnology executive.

- Received a notice of allowance of a patent by the European Patent Office for the discovery of a gene, which suppresses the growth of malignant tumors, further strengthening Lorus' intellectual property portfolio.
- Published various papers by Lorus scientists in prominent scientific journals and made presentations at some of the most influential meetings in the cancer research field.

"As Lorus grows and transforms as an organization, we continue to expand our product pipeline, relying on our experienced management team and solid financial base. We are encouraged by the ongoing clinical success of our many drug candidates as we position the company for commercial success with our lead immunotherapeutic drug, Virulizin(R)," said Dr. Jim Wright, president and CEO of Lorus. "Reaching full enrollment in our Phase III clinical trial of Virulizin(R) has been a significant achievement for Lorus, and, combined with our recent management additions and continued progress in our GTI-2040 and 2501 clinical trials, has made this a very successful first quarter."

FINANCIAL RESULTS

Net loss for the quarter ended August 31, 2004 totaled $6.2 million ($0.04 per share) compared to a loss of $8.2 million ($0.05 per share) for the same quarter last year. The decrease in net loss is due to a reduction of $2.2 million in research and development expenses and $200,000 in administrative expenses. These reductions were offset by lower interest income of $248,000 and the recognition of stock-based compensation expense of $211,000 resulting from the adoption of Canadian Institute of Chartered Accountants ["CICA"] revised Handbook Section 3870, 'Stock-Based Compensation and Other Stock-Based Payments'.

Research and development expenses for the quarter ended August 31, 2004 decreased to $5.0 million compared to $7.3 million for the same quarter last year. The decrease in costs was anticipated due to lower clinical trial costs for the fully enrolled Phase III trial of Virulizin(R) in comparison to the prior year when significant start up costs were incurred. As well in the first quarter of fiscal 2004 the Company incurred initial costs of supplying the GTI-2040 drug to the National Cancer Institute ["NCI"] for the NCI sponsored phase II clinical trial program, for which Lorus continues to have a sufficient supply on hand to complete the clinical trials.

General and administrative expenses for the first quarter of fiscal 2005 decreased $200,000 to $1.0 million compared with $1.2 million in 2004. The decrease is primarily due to severance payments incurred in the first quarter of 2004.

Stock-based compensation expense of $211,000 for the quarter ended August 31, 2004 represents the amortization of the estimated fair value of stock options granted since June 1, 2002 applicable to the current period. The retroactive application of CICA Handbook Section 3870 with respect to recognition of stock compensation expense for the 2003 and 2004 fiscal years resulted in a $2.8 million charge to the deficit and credit to the contributed surplus accounts on June 1, 2004.

Interest income for the quarter ended August 31, 2004 decreased to $145,000 from $393,000 for the same quarter last year. The decrease is attributable to a lower cash and short-term investment balance during the first quarter of 2005.

At August 31, 2004 Lorus had cash and cash equivalents and short-term investments totaling $20.7 million compared to $26.7 million at May 31, 2004. Working capital was $17.0 million at August 31, 2004 compared to $22.6 million at May 31, 2004. Subsequent to quarter end, as a result of the financing referred to above, the Company's cash and cash equivalents increased by $4.4 million due to the advancement of the first tranche. Lorus will receive $14.4 million in funds during fiscal 2005 as a result of the convertible debenture agreement discussed above.

Lorus Therapeutics Inc.
Consolidated Statements of Loss (unaudited)

(amounts in 000's except for per common share data) *(Canadian Dollars)*	**Three months ended Aug. 31, 2004**	Three months ended Aug. 31, 2003	Period from inception Sept. 5, 1986 to Aug. 31, 2004
Revenues	**$ 2**	$ 29	$ 676
EXPENSES			
Cost of Sales	**-**	-	83

Research and development	**5,049**	7,263	90,893
General and administrative	**1,025**	1,231	38,818
Stock-based compensation expense	**211**	-	214
Depreciation and amortization	**107**	99	8,888
Operating Expenses	**6,392**	8,593	138,896
Interest income	**(145)**	(393)	(10,168)
Loss for the period	**$ 6,245**	$ 8,171	$ 128,052
Basic and diluted loss per common share	**$ 0.04**	$ 0.05	
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per share	**171,801**	171,517	

See accompanying notes to unaudited consolidated financial statements

As Lorus is holding its Annual General Meeting of the shareholders on November 18, we will not hold a conference call to discuss the operating results of this quarter. Lorus always welcomes the shareholders, the financial community and the general public to contact us at any time.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin(R) is a registered trademark of Lorus Therapeutics Inc.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information forms annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: http://www.lorusthera.com.